Go Pro
NASDAQ:OPK

OPKO Health (OPK) Stock Price, News & Analysis

OPKO Health logo
$1.35 +0.04 (+3.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 -0.02 (-1.11%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About OPKO Health Stock (NASDAQ:OPK)

Advanced

Key Stats

Today's Range
$1.29
$1.36
50-Day Range
$1.17
$1.65
52-Week Range
$0.98
$1.73
Volume
2.68 million shs
Average Volume
3.05 million shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.55
Consensus Rating
Hold

Company Overview

OPKO Health, Inc. (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States. BioReference offers routine clinical testing, women’s health panels, oncology diagnostics, genetic and genomic assays, and esoteric testing to hospitals, physicians and clinical research organizations. During the COVID-19 pandemic, the laboratory network expanded testing capacity to meet growing public health needs. Beyond the U.S., OPKO’s diagnostic operations extend into Latin America, serving customers in Mexico, Brazil and Argentina.

OPKO’s Pharma Services & Products segment is dedicated to the development, licensing and commercialization of innovative therapeutics. The company’s marketed portfolio includes Rayaldee®, an FDA-approved treatment for secondary hyperparathyroidism in adults with stage 3–4 chronic kidney disease. OPKO also advances a pipeline of small molecules, biosimilars and novel biologics targeting metabolic disorders, endocrinology and oncology. Strategic collaborations and in-licensing arrangements bolster the company’s research capabilities and expand its product offerings.

Founded in 2007, OPKO has grown through strategic acquisitions—most notably the 2015 purchase of BioReference Laboratories—and partnerships with academic and industry leaders. Under the leadership of Chairman and CEO Dr. Phillip Frost, a physician-scientist and experienced biotech entrepreneur, the company emphasizes an integrated approach that combines advanced diagnostics with precision therapeutics. OPKO continues to pursue geographic expansion and pipeline diversification to meet evolving healthcare demands worldwide.

AI Generated. May Contain Errors.

OPKO Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

OPK MarketRank™: 

OPKO Health scored higher than 28% of companies evaluated by MarketBeat, and ranked 743rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OPKO Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    OPKO Health has a consensus price target of $1.55, representing about 14.4% upside from its current price of $1.36.

  • Amount of Analyst Coverage

    OPKO Health has only been the subject of 2 research reports in the past 90 days.

  • Read more about OPKO Health's stock forecast and price target.
  • Earnings Growth

    Earnings for OPKO Health are expected to decrease in the coming year, from ($0.25) to ($0.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OPKO Health is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OPKO Health is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OPKO Health has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.06% of the float of OPKO Health has been sold short.
  • Short Interest Ratio / Days to Cover

    OPKO Health has a short interest ratio ("days to cover") of 12.96, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in OPKO Health has recently increased by 3.22%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    OPKO Health does not currently pay a dividend.

  • Dividend Growth

    OPKO Health does not have a long track record of dividend growth.

  • News Sentiment

    OPKO Health has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for OPKO Health this week, compared to 4 articles on an average week.
  • Search Interest

    Only 11 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added OPKO Health to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OPKO Health insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    44.72% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.63% of the stock of OPKO Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OPKO Health's insider trading history.
Receive OPK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OPK Stock News Headlines

OPKO Health: Mazdutide And MDX-2201 Could Change Everything
OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
OPKO Health: A Hold As Progress Continues
FY2026 EPS Estimates for OPKO Health Lifted by HC Wainwright
See More Headlines

OPK Stock Analysis - Frequently Asked Questions

OPKO Health's stock was trading at $1.26 on January 1st, 2026. Since then, OPK shares have increased by 7.5% and is now trading at $1.3550.

OPKO Health, Inc. (NASDAQ:OPK) issued its earnings results on Monday, July, 27th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.07. OPKO Health's quarterly revenue was up 4.3% compared to the same quarter last year.
Read the conference call transcript
.

OPKO Health's top institutional investors include Assenagon Asset Management S.A. (0.04%) and Allied Private Wealth LLC (0.01%). Insiders that own company stock include Phillip Md Et Al Frost, Jane Ph D Hsiao, Steven D Rubin, Opko Health, Inc, John A Paganelli, Gary J Nabel, Richard C Pfenniger Jr and Richard M Krasno.
View institutional ownership trends
.

Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OPKO Health investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
7/27/2026
Today
8/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:OPK
CIK
944809
Employees
1,373
Year Founded
2007

Price Target and Rating

High Price Target
$1.60
Low Price Target
$1.50
Potential Upside/Downside
+14.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$225.68 million
Net Margins
-12.40%
Pretax Margin
-13.58%
Return on Equity
-5.88%
Return on Assets
-3.83%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
3.35
Quick Ratio
2.93

Sales & Book Value

Annual Sales
$587.90 million
Price / Sales
1.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
0.85

Miscellaneous

Outstanding Shares
746,328,000
Free Float
412,570,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
1.51

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:OPK) was last updated on 8/5/2026 by MarketBeat.com Staff.
From Our Partners